

**Nomination for President\***

Annual General Meeting, Tuesday 13 May 2025  
Joint Congress of ESPE and ESE 2025, Copenhagen, Denmark

**Form A**

\*President-elect for 2025-2027 and President 2027-2029

Please return to: Professor M Zatelli, Secretary, European Society of Endocrinology, Redwood House, Brotherswood Court, Great Park Road, Bradley Stoke, Bristol, BS32 4QW, UK or email to [info@ese-hormones.org](mailto:info@ese-hormones.org)

Please refer the [Information on the role of an ESE Executive Committee member](#) for detailed information on the role and time commitment. Important information is also detailed in the [Trustees' responsibilities: Key points for Executive Committee candidates](#).

**Closing date: Monday 6 January 2025**

1	Name of Nominee:	Ezio GHIGO
2	Nationality:	Italian
3	Email address:	ezio.ghigo@unito.it
4	Current position and geographical location:	Chair of the Department of Medicine and Endocrinology, Diabetology and Metabolism, University Hospital Città della Salute e della Scienza, University of Turin, Italy
5	Speciality in endocrinology/Main field of expertise:	Neuroendocrinology, Metabolism
6	Basic, clinical or both:	Both
7	Give details of current or previous committee experience in a national society of endocrinology or a European speciality society:	Secretary of the Italian Society of Endocrinology (SIE): 1995-1999 Eur Fed Endocrine Societies (EFES) ExCo Member: 2003-2005 ESE Vice-President: 2005-2009 Chair POC 8 <sup>th</sup> ECE congress, Budapest, 2007 President of the Italian Society of Endocrinology (SIE) 2009-2012 Geoffrey Harris Prize at ECE congress in Rotterdam: 2012
8	Give details of experience as an editor or member of an editorial board:	Editor in Chief of the Journal of Endocrinological Investigation: 2001-2009
9	List (max) 10 papers that were published in international journals within the last 6 years. Note: journals to have an impact factor of 2.0 or above.	1: Grottoli S, Ghigo E. Pituitary tumor centers of excellence (PTCOE): the next border of acromegaly treatment. Pituitary. 2024 Aug;27(4):314-316. doi: 10.1007/s11102-024-01416-w. Epub 2024 Jun 25. PMID: 38916827. 2: Bioletto F, Varaldo E, Gasco V, Maccario M, Arvat E, Ghigo E, Grottoli S. Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond. Rev Endocr Metab Disord. 2024 Nov 23. doi: 10.1007/s11154-024-09933-6. Epub ahead of print. PMID: 39579280. 3: Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2024 Nov 13. doi: 10.1038/s41574-024-01052-1. Epub ahead of print. 4: Bioletto F, Pusterla A, Fraire F, Sauro L, Presti M, Arvat E, Ghigo E, Procopio M, Barale M. Sex-specific association of chronic proton pump inhibitor use with reduced bone density and quality. J Clin Endocrinol Metab. 2024 Aug 28:dgae598. doi: 10.1210/clinem/dgae598. Epub ahead of print. PMID: 39197024. 5: Granato G, Gesmundo I, Pedrolli F, Kasarla R, Begani L, Banfi D, Bruno S, Lopatina T, Brizzi MF, Cai R, Sha W, Ghigo E, Schally AV, Granata R. Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.

		<p>Front Immunol. 2023 Aug 15;14:1231363. doi: 10.3389/fimmu.2023.1231363. PMID: 37649486; PMCID: PMC10462983.</p> <p>6: Boido M, Gesmundo I, Caretto A, Pedrolli F, Schellino R, Leone S, Cai R, Sha W, Ghigo E, Schally AV, Vercelli A, Granata R. Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice. Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2216814120. doi: 10.1073/pnas.2216814120. Epub 2023 Jan 5. PMID: 36603028; PMCID: PMC9926281.</p> <p>7: Parasiliti-Caprino M, Bioletto F, Lopez C, Maletta F, Caputo M, Gasco V, La Grotta A, Limone P, Borretta G, Volante M, Papotti M, Terzolo M, Morino M, Pasini B, Veglio F, Ghigo E, Arvat E, Maccario M. Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery. Eur J Endocrinol. 2022 Feb 15;186(3):399-406. doi: 10.1530/EJE-21-0370. PMID: 35363157.</p> <p>8: Gesmundo I, Granato G, Fuentes-Fayos AC, Alvarez CV, Dieguez C, Zatelli MC, Congiusta N, Banfi D, Prencipe N, Leone S, Brunetti L, Castaño JP, Luque RM, Cai R, Sha W, Ghigo E, Schally AV, Granata R. Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling. Cancers (Basel). 2021 Aug 5;13(16):3950. doi: 10.3390/cancers13163950. PMID: 34439107; PMCID: PMC8393969.</p> <p>9: Bioletto F, Barale M, Parasiliti-Caprino M, Prencipe N, Berton AM, Procopio M, Deandreis D, Ghigo E. Comparison of the diagnostic accuracy of 18F-Fluorocholine PET and 11C-Methionine PET for parathyroid localization in primary hyperparathyroidism: a systematic review and meta-analysis. Eur J Endocrinol. 2021 May 25;185(1):109-120. doi: 10.1530/EJE-21-0038. PMID: 33886494.</p> <p>10: Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimir F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Negggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz096. doi: 10.1210/clinem/dgz096. PMID: 31606735.]</p>
10	Give details of any experience with EU funding:	[EU VI° Framework Program DIABESITY]